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INTRODUCTION
Allergen immunotherapy (AIT) with allergens has been used 
as the only specific treatment of allergic diseases, such as aller-
gic mild asthma, allergic rhinitis, and bee venom anaphylaxis.1,2 
There have been several reports of the positive effects of AIT in 
atopic dermatitis, suggesting that AIT may also have a thera-
peutic value in the treatment of atopic dermatitis.3,4 AIT may 
change the natural course of the disease and has several disease-
modifying effects. Randomized clinical trials have shown that 
AIT can decrease symptom-medication scores by 30%-40%.5,6 
In addition, the effects of AIT can be maintained long after the 
discontinuation of AIT, particularly when it is performed for 3 
years or longer.7,8 Furthermore, AIT can prevent the develop-
ment of allergic asthma in allergic rhinitis patients9-11 and new 
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sensitization in children with house dust mite mono-sensitized 
asthma.12,13 
In Korea, prescription of AIT is not popular compared to that 
in Western countries, and data on the current prescription pat-
tern of AIT in Korea are not available. Therefore, we conducted 
a survey of the prescription pattern of Korean allergy specialists 
and analyzed underlying causes of the low AIT prescription 
rate in Korea. 
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Purpose: Allergen immunotherapy (AIT) has been used as a curative and specific treatment of allergic diseases. However, no data on the prescrip-
tion patterns of AIT in Korea is available. Therefore, we surveyed the prescription patterns of AIT by allergy specialists in Korea. Methods: We 
emailed a questionnaire on AIT prescription patterns to the 690 members of the Korean Academy of Asthma, Allergy and Clinical Immunology 
(KAAACI) with clinical practice experience. All returned answers were evaluated. Results: The response rate was 21.0%. Only 69.0% of the re-
spondents performed AIT in practice. Hindrance factors for performing AIT in the practice included a lack of facilities (21%), lack of practical experi-
ence during their subspecialty or postgraduate educational training programs (15.8%), no need for AIT because of sufficient pharmacotherapy 
(14.5%), insufficient economic profits (14.5%), and risks for adverse reactions (13.2%). Ninety-two allergy specialists (82%) performed AIT subcuta-
neously subcutaneous immunotherapy (SCIT) and 20 allergy specialists (18%) performed it sublingually sublingual immunotherapy (SLIT). Only 8 spe-
cialists performed both SCIT and SLIT. The allergens used for SCIT were house dust mites (98.9%), pollens (72.8%), and animal dander (23.9%). SLIT 
was prescribed only for house dust mites. Twenty-eight physicians (30.4%) observed anaphylactic reactions during SCIT. Eight physicians (40.0%) 
who prescribed SLIT observed adverse reactions, including local reactions, but none of them observed anaphylactic reactions. Conclusions: In 
this survey, 69.0% of the respondents performed AIT in clinical practice. SCIT prescription is more popular than SLIT. The Lack of facilities and clini-
cal education is a critical barrier to performing AIT. Therefore, proper clinical education of AIT is necessary for Korean allergists.
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MATERIALS AND METHODS
We emailed a questionnaire on AIT prescription patterns to 
the 690 members of the Korean Academy of Asthma, Allergy 
and Clinical Immunology (KAAACI) with clinical practice ex-
perience. We obtained responses to the questionnaire by Au-
gust 2009. The questionnaire was again circulated to the same 
Academy members at 1-month intervals in order to increase 
the response rate. The questionnaire consisted of 24 questions 
regarding practice patterns. The questionnaire included demo-
graphics, insight into AIT for the treatment of allergic disease, 
practice patterns of AIT, and adverse reactions during AIT. The 
detailed questionnaire is shown in Figure. All returned answers 
were evaluated and analyzed using descriptive statistics.
RESULTS
Characteristics of the respondents
Table 1 shows the characteristics of the respondents. We ob-
tained responses from 145 (21.0%) of the 690 members mem-
bers. Of these who respondents, 67 (42.8%) were in their 30s, 47 
(32.4%) were in their 40s, and 20 (13.8%) were in their 50s. Five 
respondents (3.4%) were at the age of over 60 years. The majori-
ty (75.2%) of the respondents were in their 30s and 40s. Of these 
respondents, 62 (42.8%) were physicians, 47 (32.4%) were pedi-
atricians, 30 (20.7%) were otolaryngologists, and 2 (1.4%) were 
dermatologists. Approximately half of the respondents (49.0%) 
worked at university hospitals, 46 (31.7%) worked at general 
hospitals, and the remaining (19.3%) worked at private clinics. 
The institutes of more than half (62.1%) of the respondents were 
located in Seoul and its metropolitan area.
Insights into AIT
Most respondents agreed on the necessity of AIT to treat aller-
gic diseases (143/145, 98.6%). However, only 100 (69.0%) were 
currently using AIT in their practice. Although the remaining 45 
(31.0%) were not yet using AIT, 30 (20.7%) respondents desired 
to use it in the future practice. Table 2 shows the obstacles to 
starting AIT in their own practice based on responses from the 
members without AIT experience. The most frequent reason 
was lack of facilities, including lack of trained health profession-
als (35.5%), and lack of practical AIT experience during the 
training course of their subspecialty (26.7%). Some respon-
dents answered that they did not trust therapeutic effects of AIT 
Figure. Questionnaire regarding allergen immunotherapy (AIT) sent to the Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI) members.
SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.
A Survey of Allergen Immunotherapy in Korea
Allergy Asthma Immunol Res. 2013 September;5(5):277-282. http://dx.doi.org/10.4168/aair.2013.5.5.277
AAIR 
279http://e-aair.org
(17.8%); they thought AIT was unnecessary because pharma-
cotherapy alone was sufficient for the management of allergic 
diseases (24.4%). These respondents also reported that AIT did 
not provide enough economic profits (24.4%) considering the 
risks of serious adverse events (22.2%). 
AIT in practice
Table 3 shows target diseases for which the respondents used 
AIT. Allergic rhinoconjunctivitis (92.0%), allergic asthma 
(76.0%), atopic dermatitis (20.0%), and bee sting anaphylaxis 
(10.0%) were ranked as the major indications. We asked the 
methods used to detect causative allergens and found that skin 
prick tests and serologic tests, including ImmunoCAP, RAST, 
and MAST, were all popular for the diagnosis of causative 
agents (94.0% vs. 100.0%). Approximately 94.0% of the respon-
dents used both skin prick tests and serologic tests for the iden-
tification of culprit allergens. 92 of all allergy specialists, (82.0%) 
performed subcutaneous immunotherapy (SCIT) and 20 (18.0%) 
performed sublingual immunotherapy (SLIT). Only 8 allergy 
specialists performed both SCIT and SLIT. The respondents 
who performed SCIT were asked as to which allergens they 
used for SCIT. House dust mite (98.9%) was the most common 
allergen for SCIT, followed by pollen allergens (72.8%), animal 
dander (23.9%), and fungal species (20.7%) (Table 4). In addi-
tion, 13.2% of the respondents did not prescribe poly allergens 
for SCIT, whereas the remaining respondents prescribed com-
bined up to poly allergens containing 5 different allergen ex-
tracts. Only 10.9% of the respondents mixed and prepared the 
allergen extract from bulk extracts at their clinics. The remain-
ing respondents used a tailor-made extract set provided by 
pharmaceutical companies. For the build-up phase, 72.3% of 
the respondents used a conventional schedule of increasing 
doses of allergen immunotherapy extract administered 1-2 
times per week, whereas 16.0% used a rush protocol and 11.8% 
used a cluster schedule protocol. Only house dust mites were 
prescribed for SLIT in Korea.
Table 1. Characteristics of the survey respondents
n (%)
Number of respondents 145 (21.0)
Age (years)
31-40 67 (42.8)
41-50 47 (32.4)
51-60 20 (13.8)
≥ 61 5 (3.4)
Specialty
Internal medicine 62 (42.8)
Pediatrics 47 (32.4)
Otolaryngology 30 (20.7)
Dermatology 2 (1.4)
Others 4 (2.8)
Location of work
University hospital 71 (49.0)
General hospital 46 (31.7)
Private clinic 28 (19.3)
Province of work
Seoul 52 (35.9)
Gyeonggi 38 (26.2)
Busan 8 (5.5)
Gwangju 9 (6.2)
Daegu 7 (4.8)
Daejeon 2 (1.4)
Ulsan 3 (2.1)
Others 26 (17.9)
Table 2. Reasons for not performing allergen immunotherapy
n (%)
Lack of facilities 16 (35.5)
Lack of experience 12 (26.7)
Distrust of therapeutic effect 8 (17.8)
Unnecessary for management of allergic diseases 11 (24.4)
Risk of adverse reactions 10 (22.2)
Little profit to doctor 11 (24.4)
Other 8 (17.8)
All respondents 45 (100.0)
Numbers are not mutually exclusive.
Table 3. Diseases indicated for allergen immunotherapy
n (%)
Bronchial asthma 76 (76.0)
Allergic rhinoconjunctivitis 92 (92.0)
Atopic dermatitis 20 (20.0)
Bee venom allergy 10 (10.0)
Food allergy 1 (1.0)
All respondents 100 (100.0)
Numbers are not mutually exclusive.
Table 4. Culprit allergens for subcutaneous immunotherapy
n (%)
House dust mite 91 (98.9)
Pollens (e.g., tree, weed, etc.) 67 (72.8)
Animal dander 22 (23.9)
Molds 19 (20.7)
Bee venom 10 (10.9)
Cockroach 5 (5.4)
Other 0 (0.0)
All respondents 92 (100.0)
Numbers are not mutually exclusive.
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Adverse reactions during AIT
Twenty-eight (30.4%) of the 92 SCIT respondents reported 
anaphylaxis during the SCIT. Of the 20 SLIT respondents, none 
reported anaphylaxis, but 8 (40.0%) reported adverse local re-
actions, including oral swelling and itching sensations of the 
throat or tongue.
DISCUSSION
Numerous similar surveys of AIT prescription patterns have 
been conducted in Mexico,14 Italy,15 and the United States.16,17 In 
addition, a worldwide survey of AIT practice patterns which fo-
cused on AIT doses and durations has been published recent-
ly.18 In this study, 69.0% of the allergy specialists in Korea used 
AIT. This figure may be higher than that of all Korean allergy 
practitioners. Most respondents to our survey were physicians, 
pediatricians, and otolaryngologists. They were generally young 
(between ages of 30 and 40) and worked at general hospitals lo-
cated in Seoul and Gyeonggi-do Province, the metropolitan 
area of Korea. Young allergists are willing to accept recent infor-
mation and to update their medical skills. People living in Seoul 
and its vicinity show higher prevalences of atopic diseases, in-
cluding allergic rhinitis, asthma, and atopic dermatitis. They 
had higher socioeconomic statuses and were more interested 
in AIT than people living in other regions in Korea. Most respon-
dents practiced at university hospitals and only a few worked at 
private clinics. This reflects the composition of KAAACI mem-
bers. Most Korean allergy specialists are working at university 
hospitals, which is quite different from Western allergy special-
ists.
Regarding the need for AIT, most Korean allergists (98.6%) 
agreed to its role in the treatment of allergic diseases. However, 
some were reluctant to recognize this role because 17.8% of the 
respondents did not believe the efficacy of AIT in managing al-
lergic diseases. One-third of the respondents did not prescribe 
AIT in clinical practice. Lack of facilities, including lack of trained 
health professionals, and lack of instruction on how to perform 
AIT through training or postgraduate programs were the most 
common reasons for not prescribing it. 
Diseases indicated for SCIT include allergic rhinoconjunctivi-
tis (92.0%), asthma (76.0%), atopic dermatitis (20.0%), and bee 
sting anaphylaxis (10.0%) in this study. It suggests that allergic 
asthma and rhinoconjunctivitis are the main diseases treated 
with AIT in Korea. The role of AIT for the management of aller-
gic rhinoconjunctivitis and bee sting anaphylaxis is apparent,19,20 
but it is controversial for asthma management.20-22 AIT is pre-
scribed more frequently for allergic asthma in Korea than in 
other countries. This may be because the majority of KAAACI 
members are physicians trained in the Department of Internal 
Medicine and they more focus on the treatment of allergic asth-
ma than on allergic rhinoconjunctivitis. Another reason is that 
Korean allergy specialists are in favor of AIT for the management 
of atopic dermatitis. Recently, favorable data from randomized 
and nonrandomized clinical trials of AIT in atopic dermatitis 
have been reported.4,23-25 
Both skin prick and serologic tests are popularly used to de-
termine offending allergens. Skin tests are performed for screen-
ing in most allergy clinics (94%) and serologic tests, including 
ImmunoCAP, RAST, and MAST, are used to confirm the pres-
ence of specific IgE. 
House dust mites are the most common culprit allergen, fol-
lowed by pollen allergens, animal dander, and fungal species, 
which are consistent with the prevalences of offending aller-
gens in Korea.26 Korean allergists are prudent in the identifica-
tion of offending allergens. They use skin prick tests for screen-
ing and confirm the presence of specific IgE by serologic tests. 
In Korea, poly allergen immunotherapy is more popular than 
mono-allergen immunotherapy. Only 13.2% of the respondents 
used a single allergen extract, such as house dust mite alone, 
whereas most respondents prescribed mixed allergen extracts 
in multiple-sensitized patients. The cross-reactivity of allergens, 
dose optimization of each constituent, and enzymatic degrada-
tion of allergens must be considered when allergen extracts are 
mixed.27 KAAACI recommended a mixture of up to 5 different 
allergens.28 For the immunotherapy schedule, only 25% of the 
respondents performed rush or cluster AIT in the build-up 
phase. AIT was administered by physicians (37%) or nurses 
(63%). 
Only 13.8% of the respondents prescribed SLIT in clinical 
practice; most were otolaryngologists. Because SLIT was intro-
duced in Korea 2 years prior to our study, a relatively low pre-
scription rate was expected compared to SCIT. More clinical ex-
periences are needed for SLIT to be prescribed widely by physi-
cians and pediatricians. 
The frequency of adverse systemic reactions during SCIT has 
been reported to be 2.1%-2.9% of all patients.29 In this survey, 
~30% of the respondents observed severe systemic reactions af-
ter SCIT. SLIT is known to be safer than SCIT because few cases 
of severe systemic reactions have been reported during SLIT.30 
In this study, no respondents observed severe systemic reactions 
to SLIT, but 40% had local adverse reactions, including oral 
swelling and itching. 
In conclusion, 69.0% of the respondents performed AIT in 
clinical practice. The prescription of SCIT is more popular than 
SLIT; however, SLIT is increasingly prescribed, particularly 
among otorhinolaryngologists. Lack of facilities, including 
trained health professionals, and lack of clinical experience and 
instruction on AIT are the critical barriers to the prescription of 
AIT by Korean allergy specialists. Therefore, proper clinical in-
struction that introduces and updates information on AIT is 
necessary to encourage AIT in Korea. 
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